Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHaleon Share News (HLN)

Share Price Information for Haleon (HLN)

Share Price is delayed by 15 minutes
Get Live Data
321.20    0.30 (0.09%)
Bid:
320.40
Ask:
320.50
Spread: 0.10 (0.031%)
Market Cap: £28.42b
HLN Live PriceLast checked at - London Stock Exchange

Intraday Haleon Share Chart

Haleon fourth quarter sales growth pegged by weak cold and flu season

Wed, 25th Feb 2026 09:04

(Alliance News) - Haleon PLC on Wednesday reported lower than expected fourth quarter organic sales growth held back by a weak flu and cold season.

The consumer healthcare firm which owns brands such as Sensodyne oral care products and painkiller Panadol said pretax profit improved 13% to GBP2.15 billion in 2025 from GBP1.91 billion the year prior.

Operating profit picked up 9.0% to GBP2.41 billion from GBP2.21 billion. Basic earnings per share improved 18.6 pence from 15.8p, or to 18.5p from 15.7p on a diluted per share basis.

However, revenue fell 1.8% to GBP11.03 billion from GBP11.23 billion, with organic revenue growth of 3.0%, below its medium-term guidance of 4% to 6% annual organic revenue growth.

In the fourth quarter, organic sales growth was 2.1% below consensus of 3.5%.

Haleon said a headwind from a weak cold and flu season was estimated to be a 150 basis points impact in the fourth quarter and around 40 bps for the full-year.

In response, shares in Haleon fell 4.0% to 389.30 pence each in London on Wednesday.

Chief Executive Brian McNamara said: "Organic revenue growth of 3% was below our medium-term expectations, primarily reflecting a weak cold flu season and low consumer confidence in North America. We delivered strong gross margin improvement and double-digit organic profit growth, combined with strong cash generation."

Gross margin improved 350 basis points to 64.2% and by 22 bps to 65.2% on an adjusted basis.

For 2025, North America reported an organic sales decline of 0.4%, while sales grew 4.4% in Europe, Middle East & Africa and Latin America, and 5.2% in Asia-Pacific.

Oral Health organic sales rose 7.9%, VMS sales by 1.9%, Pain Relief by 2.3% and Digestive Health by 0.5% in 2025 on-year. But sales in Respiratory Health fell 1.9%.

For 2026, Haleon expects 3% to 5% organic revenue growth, compared to 4.4% consensus, and its 4% to 6% mid-term guide.

The firm predicts "high-single digit adjusted operating profit growth at constant currency".

It expects a foreign exchange translation headwind, hitting net revenue and adjusted operating profit by around 1%.

In addition, it announced it has allocated GBP500 million into buybacks in 2026.

Haleon upped its final dividend by 6.5% to 4.9 pence per share from 4.6p. It meant for a total dividend of 7.1p per share, up 7.6% from 6.6p.

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Market Reports Corporate News Pharmaceuticals Health Care

Related News

EARNINGS AND TRADING: ATC revenue rises; First Class disposal update
5 hours ago

EARNINGS AND TRADING: ATC revenue rises; First Class disposal update

(Alliance News) - The following is a round-up of trading updates by London-listed companies, issued on Wednesday and not separately reported by Allian...

EARNINGS AND TRADING: Vaultz Capital ousts CEO Benz, promotes Wood
5 hours ago

EARNINGS AND TRADING: Vaultz Capital ousts CEO Benz, promotes Wood

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...

MultiChoice owner Canal+ debuts on JSE in secondary listing
7 hours ago

MultiChoice owner Canal+ debuts on JSE in secondary listing

(Alliance News) - Canal+ SA on Wednesday listed on the Johannesburg Stock Exchange, becoming the first ever French company to list on the bourse.

Haleon News

LONDON BROKER RATINGS: Citi cuts Severn Trent and United Utilities
5 May 2026

LONDON BROKER RATINGS: Citi cuts Severn Trent and United Utilities

(Alliance News) - The following London-listed shares received analyst recommendations on Tuesday morning and on Monday:

LONDON BROKER RATINGS: UBS, Goldman and Citi say 'buy' Lloyds Banking
30 Apr 2026

LONDON BROKER RATINGS: UBS, Goldman and Citi say 'buy' Lloyds Banking

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

LONDON MARKET MIDDAY: FTSE falls as blue chips weigh on market
29 Apr 2026

LONDON MARKET MIDDAY: FTSE falls as blue chips weigh on market

(Alliance News) - Stock prices in London extended losses by midday Wednesday, as weakness among blue chips outweighed strength in smaller caps.

WINNERS & LOSERS: Treatt agrees to takeover; Futura swing to loss
29 Apr 2026

WINNERS & LOSERS: Treatt agrees to takeover; Futura swing to loss

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Wednesday.

WINNERS & LOSERS: Pharma in the red; DCC jumps after takeover approach
29 Apr 2026

WINNERS & LOSERS: Pharma in the red; DCC jumps after takeover approach

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Wednesday.

Haleon stands by full-year outlook as revenue edges higher
29 Apr 2026

Haleon stands by full-year outlook as revenue edges higher

(Alliance News) - Haleon PLC on Wednesday reported increased quarterly revenue and reiterated its growth forecasts for the year.